SCHEMBL353155

SCHEMBL353155

O=C(NC1=CC(=O)C2OC2C1O)c1cc(Cl)cnc1O

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.48
KDR P35968 1/20 0.33
KCNMA1 Q12791 2/20 0.32
TMPRSS4 Q9NRS4 2/20 0.31
P2RX1 P51575 2/20 0.31
P2RX4 Q99571 2/20 0.31
P2RX7 Q99572 2/20 0.31
F10 P00742 1/20 0.31
NPC1 O15118 1/20 0.30
ALOX15 P16050 1/20 0.30
HTT P42858 1/20 0.30
RAB9A P51151 1/20 0.30
JUN P05412 1/20 0.30
NFKB1 P19838 1/20 0.30
NFKB2 Q00653 1/20 0.30
RELA Q04206 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL666185 0.81 P2RX1 (0.51) PARK7KDRKCNMA1TMPRSS4P2RX1
SCHEMBL665039 0.79 PARK7 (0.50) PARK7KCNMA1TMPRSS4P2RX1P2RX4
SCHEMBL665474 0.79 PARK7 (0.49) PARK7KDRKCNMA1TMPRSS4P2RX1
SCHEMBL351666 0.78 PARK7 (0.46) PARK7KDRKCNMA1TMPRSS4P2RX1
SCHEMBL352102 0.76 PARK7 (0.47) PARK7
SCHEMBL352808 0.75 PARK7 (0.46) PARK7
SCHEMBL351849 0.75 PARK7 (0.45) PARK7
Dehydroxymethylepoxyquinomicin SCHEMBL14491796 0.74 PARK7 (0.54) PARK7KCNMA1P2RX1P2RX4P2RX7
Dehydroxymethylepoxyquinomicin SCHEMBL1671089 0.74 PARK7 (0.54) PARK7KCNMA1P2RX1P2RX4P2RX7
SCHEMBL353426 0.74 PARK7 (0.46) PARK7NPC1HTTRAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP claimed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US claimed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US claimed
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
EP-2411376-A1 INHIBITORS OF NF-KB Profectus Biosciences, Inc. (US) 2012-02-01 EP disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed
WO-2010111460-A1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG PARK7 3327/4885KDR 1765/4885KCNMA1 2171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.